In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood . Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. Featured Articles: Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia
